Nikkei ends flat despite strong chip makers

  • Reuters
  • Stock Market News
Nikkei ends flat despite strong chip makers
Credit: © Reuters.

* Eisai tumbles to daily limit-low

* Eisai's news reminds market of SanBio's crash - analysts

* Financials tumble as U.S. yields fall

By Ayai Tomisawa

TOKYO, March 22 (Reuters) - Japan's Nikkei ended little changed on Friday as chip-related stocks offset weakness in financial stocks and drugmakers, which tumbled after Eisai said it will end its Alzheimer drug trials.

The Nikkei share average .N225 closed up a scant 0.1 percent at 1,627.34 points, after flitting in and out of positive and negative territory. The index rose 0.8 percent for the week.

The broader Topix .TOPX rose 0.2 percent to 1,617.11.

Chip equipment makers jumped, tracking a rise in U.S. tech shares overnight. Advantest Corp 6857.T soared 6.2 percent and Tokyo Electron 8035.T surged 5.2 percent.

But financial stocks sold off after the spread between the three-month Treasury bill yield and the 10-year note yield shrank to its narrowest level since August 2007 on Thursday in the wake of the U.S. Federal Reserve's decision to cease tightening monetary policy.

A narrower spread between the three-month US3MT=RR and 10-year yields US10YT=RR indicates increased market expectations of a recession.

"The U.S. tech sector's recovery is indicating that growth stocks are making a come back," said Norihiro Fujito, a chief investment strategist at Mitsubishi UFJ Morgan Stanley (NYSE: MS ) Securities.

"On the other hand, financial stocks are under pressure reflecting the Fed's dovish stance."

Insurers and banks, which seek higher yielding products such as U.S. bonds, tumbled. T&D Holdings 8795.T dropped 1.1 percent, Dai-ichi Life Holdings 8750.T shed 1.2 percent and Mitsubishi UFJ Financial Group 8306.T dropped 0.5 percent.

The drug sector .IPHAM.T was also in the spotlight, diving 3 percent and was the worst performer on the board.

Eisai Co 4523.T nose-dived 17 percent to a daily-limit low of 7,565 yen after the drugmaker and its partner Biogen Inc BIIB.O said they are ending two trials of their experimental Alzheimer's disease drug aducanumab. news dragged down other pharmaceutical names such as Astellas Pharmaceutical 4503.T , which plunged 3.5 percent and Takeda Pharmaceutical 4502.T , which fell 0.7 percent.

"It's a blow to hopes for new treatment as this Alzheimer's drug was one of the drugs which had been expected to succeed," said Yoshihiro Okumura, a general manager at Chibagin Asset Management.

He said that Eisai's news reminded the market of SanBio Co's 4592.T crash in January, when investors were disappointed with news that it and Dainippon Sumitomo Pharma Co 4506.T saw their joint drug's clinical trial in the United States did not succeed. is a common point with SanBio's case whose shares had been rising on expectations but crashed," said Okumura, adding that its Alzheimer's drug's failure was a warning to investors that they should not be overly optimistic about drugmakers' research and development. (Editing by Kim Coghill)

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles